The first Greater Bay Area Future Health Industry Conference recently opened, with the Guangzhou municipal Industrial and Information Technology Bureau awarding licenses to four major biopharmaceutical value parks, including the Huangpu International Biopharmaceutical Value Park.
Located in the northwest of the Sino-Singapore Guangzhou Knowledge City, the Huangpu International Biopharmaceutical Value Park covers an area of approximately 1.7 square kilometers and is dedicated to establishing a high-end biopharmaceutical manufacturing hub and a leading bio-pharmaceutical base in Asia.
Huangpu International Biopharmaceutical Value Park. [Photo/WeChat account: guangzhougaoxinqu]
The park is committed to advancing research and development in new pharmaceuticals, high-end medical devices, biomedicine testing and treatment technologies, as well as medical health services. It seeks to achieve this by introducing strategic projects, optimizing the organization of biopharmaceuticals, and promoting collaboration among technology-driven enterprises, specialized medical institutions, and academic organizations, aiming to accelerate the on-site transformation of scientific innovations into practical applications.
The parks of Guangzhou engage in complementary competition and coordinated development, each serving a distinct purpose. Huangpu Park is dedicated to strengthening the supply chain for innovative pharmaceuticals. Nansha Park focuses on enhancing fundamental research and the integration of capital. Yuexiu Park facilitates the clinical transformation and market circulation of medical advancements, while Liwan Park works to integrate traditional Chinese medicine resources with contemporary technology.
In recent years, the biopharmaceutical industry in Huangpu has rapidly expanded in scale, with continuous improvement in scientific and technological innovation levels. Looking ahead, the expectation is for the rapid rise of a 100-billion-yuan ($13.7-billion) biopharmaceutical industry in Huangpu.